Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Do CYP3A and ABCB1 genotypes influence the plasma concentration and clinical outcome of donepezil treatment?

European journal of clinical pharmacology - 1 Jan 2011

Magliulo Laura, Dahl Marja-Liisa, Lombardi Grazia, Fallarini Silvia, Villa Laura Maria, Biolcati Aldo, Scordo Maria Gabriella

Abstract excerpt

PURPOSE: The aim of our study was to evaluate the impact of CYP3A4, CYP3A5, and ABCB1 polymorphisms on donepezil disposition and clinical outcome. METHODS: Fifty-four Italian patients diagnosed with probable mild to moderate Alzheimer's disease, treated with donepezil (37 patients 5 mg/day, 17 patients 10 mg/day) were genotyped for CYP3A4 (*1B, *3, and *4), CYP3A5 (*2, *3, and *6) and ABCB1 (3435C>T, 2677G>T/A,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged, 80 and over
Share to Alzheimer Disease

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to ATP Binding Cassette Transporter, Subfamily B

Share to ATP Binding Cassette Transporter, Subfamily B, Member 1

Share to Cytochrome P-450 CYP3A

Share to Indans

Share to Piperidines

Share to Treatment Outcome

Source

Identifiers

PMID: 20931330
DOI: 10.1007/s00228-010-0883-5

Genes

ABCB1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Do CYP3A and ABCB1 genotypes influence the plasma concentration and clinical outcome of donepezil treatment?PMID 20931330Read ↗

Effect of the CYP2D6 and APOE Polymorphisms on the Efficacy of Donepezil in Patients with Alzheimer's Disease: A Systematic Review and Meta-Analysis.Semantic proximity Read ↗

Impact of the CYP2D6 polymorphism on steady-state plasma concentrations and clinical outcome of donepezil in Alzheimer's disease patients.Semantic proximity Read ↗

Impact of the CYP2D6 single nucleotide polymorphism on the concentration of and therapeutic response to donepezil in mild-to-moderate Alzheimer's disease.Semantic proximity Read ↗

Pharmacogenetic Aspects of Therapy with Cholinesterase Inhibitors: The Role of CYP2D6 in Alzheimers Disease PharmacogeneticsSemantic proximity Read ↗

Impact of CYP2D6 and CYP3A4 genetic polymorphism on combined cholinesterase inhibitors and memantine treatment in mild to moderate Alzheimer's disease.Semantic proximity Read ↗

Population pharmacokinetic approach to evaluate the effect of CYP2D6, CYP3A, ABCB1, POR and NR1I2 genotypes on donepezil clearance.Semantic proximity Read ↗

The impact of ABCB1 gene polymorphism (C3435T) and its expression on response to Donepezil in Moroccan patients with Alzheimer's diseaseSemantic proximity Read ↗

The clinical impact of ABCB1 polymorphisms on the treatment of psychiatric diseases.Semantic proximity Read ↗

Replication Study to Confirm the Role of CYP2D6 Polymorphism rs1080985 on Donepezil Efficacy in Alzheimer's Disease PatientsSemantic proximity Read ↗

Therapeutic Drug Monitoring of Rivastigmine and Donepezil Under Consideration of CYP2D6 Genotype-Dependent Metabolism of Donepezil.Semantic proximity Read ↗

Effect of CYP2D6*10 and APOE polymorphisms on the efficacy of donepezil in patients with Alzheimer's disease.Semantic proximity Read ↗

Effect of a CYP2D6 polymorphism on the efficacy of donepezil in patients with Alzheimer disease.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.